Double-Target cell therapy takes on tough blood cancers
NCT ID NCT07519187
First seen Apr 16, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This early-phase study tests a new treatment called CAR70-BCMA CAR-T for people with plasma cell cancers (like multiple myeloma) that have returned or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to attack two cancer targets at once. The main goals are to check safety and find the best dose in 20 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY PLASMA CELL NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
General Hospital of Western Theater Command of PLA
Chengdu, Chengdu, China
Conditions
Explore the condition pages connected to this study.